Skip to main content
. Author manuscript; available in PMC: 2020 May 10.
Published in final edited form as: J Control Release. 2019 Mar 11;301:54–61. doi: 10.1016/j.jconrel.2019.03.008

Figure 1. Targeting of anti-ICAM-1 monoclonal antibody to the inflamed brain.

Figure 1.

Biodistribution of radiolabeled IgG or anti-ICAM-1 in control or TNFα-injured animals one hour after IV injection. (A) blood, (B) lungs, (C) brain. %ID/g: percent of injected dose per gram of tissue, ISI: immunospecificity Index (ratio (blood normalized anti-ICAM-1/liposomes in brain)/(blood normalized IgG/liposomes in brain)). *** (p<0.001, IgG vs anti-ICAM-1), ### (p<0.001, anti-ICAM-1: Control vs TNFα), one-way ANOVA (Bonferroni post-hoc analysis). Mean±SD, controls n=6, TNFα IgG n=8, and TNF anti-ICAM-1 n=7.